Aug 22, 2011, 06.58 PM | Source: Moneycontrol.com
Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma (Glaxo), in its August 10, 2011 research report.
, Angel Broking |
“GlaxoSmithKline Pharma (Glaxo) reported its 2QCY2011 results, which were mostly in-line with our estimates on the top-line and PAT level. However, the company’s OPM came in lower than our expectation at 33.2% (estimated 34.7%). We remain Neutral on the stock. Glaxo reported net sales of Rs 560cr (Rs 498cr), up 12.5% yoy, in-line with our estimates of Rs 563cr. Gross margin at 63.2% was mostly in-line with our expectations; however, OPM at 33.2% (36.5%) was below our estimate of 34.7%. The company reported net profit of Rs 148cr (Rs 129cr), growth of 14.4% yoy. This was broadly in-line with our expectation of Rs 154.4cr. The company reported net profit growth on the back of higher-than-expected other income, despite lower-than-expected OPM.”
“We expect net sales to post a 13.9% CAGR to Rs 2,788cr and EPS to register a 14.6% CAGR to Rs 86.9 over CY2010–12E. At current levels, the stock is trading at 29.5x and 24.4x CY2011E and CY2012E earnings, respectively. We maintain our estimates and, hence, remain Neutral on the stock,” says Angel Broking research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click here
GlaxoSmithKline Pharmaceuticals Q3 results on Feb 10, 2016
GlaxoSmithKline Pharmaceuticals' board meeting wil
Pharma sector hiring likely to see 20% growth in 2016: Report
The pharma and healthcare sector is looking at an
Prefer Alembic Pharma: Mehraboon Irani
Mehraboon Irani of Nirmal Bang Securities is of th
Prefer pharma, Alembic Pharma looks interesting: Dipan Mehta
Dipan Mehta, Member at BSE & NSE is of the view th
'Pharma cos to see muted exports, stable revenues in FY17'
The overall pharmaceutical exports are expected to
Look at Cadila Healthcare, Dishman Pharma: Jai Bala
Jai Bala of Cashthechaos.com is of the view that o
BFSI, retail, pharma to be impacted most by Ind AS: Survey